Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.
Posts Tagged ‘NASDAQ:KYMR’
11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds
As per the US Bank, the healthcare in the US exhibits a large and intricate ecosystem, which is characterized by size, complexity, and influence on the broader national economy...
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds.
Kymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 Degrader
B. Riley raised Kymera Therapeutics, Inc.’s (NASDAQ:KYMR) price target from $38 to $60, upgrading it from Neutral to Buy on June 3, 2025.
Morgan Stanley Maintains Hold Rating on Kymera Therapeutics (KYMR), Keeps PT
On June 2, analyst Vikram Purohit from Morgan Stanley maintained a Hold rating on Kymera Therapeutics, Inc. (NASDAQ:KYMR) with a price target of $49.
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating
On Monday, June 2, Citi analysts increased the price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) from $52 to $60 and kept a “Buy” rating.
BofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51
On June 2, Kymera Therapeutics Inc.
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621
On June 2, Kymera Therapeutics Inc.
Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday
We recently published a list of These 10 Stocks Blew Past Expectations.
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is set to unveil results from its Phase 1 clinical trial of KT-621, a first-in-class oral STAT6 degrader, on Monday, June 2, 2025.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript May 9, 2025Kymera Therapeutics, Inc. beats earnings expectations.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript February 27, 2025Kymera Therapeutics, Inc. misses on earnings expectations.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter 2024 Results Conference Call. All participants will be in listen-only mode.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Kymera Therapeutics Second Quarter 2024 Results Call. [Operator Instructions] Please note, this event is being recorded.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Kymera Therapeutics First Quarter 2024 Results Conference Call. All participants will be in the listen-only mode.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript
Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.44.
12 Most Promising Cancer Stocks According to Analysts
In this piece, we will take a look at the 12 most promising cancer stocks according to analysts.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter 2023 Results Call. [Operator Instructions]. Please note that this event is being recorded.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2023 Earnings Call Transcript
Operator: Hello and welcome to the Kymera Therapeutics Second Quarter 2023 Quarterly Results Call. I'd now like to turn the call over to Bruce Jacobs. Mr.
12 Stocks with Biggest Upside Potential According to Analysts
In this article, we will take a look at the 12 stocks with biggest upside potential according to analysts.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Kymera Therapeutics First Quarter 2023 Earnings Conference Call [Operator Instructions].
12 Small-Cap Stocks With Insider Buying
Insider buying refers to a company's officers, directors, or major shareholders purchasing shares of their own company's stock.
15 Most Shorted Stocks Right Now on Wall Street
In this article, we will look at the 15 most shorted stocks on Wall Street right now.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2022 Earnings Call Transcript
Operator: Hello, and welcome to the Kymera Therapeutics Fourth Quarter 2022 Earnings Conference Call. Please note, this event is being recorded.
Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Cathie Wood, Dan Sundheim, Tiger Global Management, Aurelius Capital Management, Tarsus Pharmaceuticals Inc (TARS), Appian Corporation (APPN), and More
Hedge fund manager Bill Ackman and Peter Thiel, an ally of former President Donald Trump, are backing a startup investing firm that says it plans to go head to head against large...
Top 10 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying
In this article we present the list of Top 10 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying.
Is Kymera Therapeutics, Inc. (KYMR) A Good Stock To Buy?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
5 Best Biotech Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund
In this article, we discuss the 5 best biotech stocks to buy according to Mark Lampert.
Hedge Fund and Insider Trading News: Paul Marshall, Tom Steyer, Michael Burry, Bill Ackman, Tiger Global Management, SRS Investment Management, Blackstone Mortgage Trust Inc (BXMT), Kymera Therapeutics Inc (KYMR), and More
Tom Steyer, the former hedge fund executive, billionaire, and Democratic presidential candidate has become one of the leading activist investors on climate change.
10 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund
In this article, we examined Mark Lampert’s investment philosophy and decades of experience in the biotechnology space.
Hedge Funds Are Betting On Kymera Therapeutics, Inc. (KYMR)
While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors...
Is KYMR Stock A Buy or Sell?
In this article we will analyze whether Kymera Therapeutics, Inc.
Is KYMR A Good Stock To Buy Now According To Hedge Funds?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money ...
